Search

Since 2007, the Oncofertility Consortium Annual Conference has brought together a diverse network of individuals from a wide range of backgrounds and professional levels to disseminate emerging basic and clinical research findings in fertility preservation. This network also developed enduring educational materials to accelerate the pace and quality of field-wide scientific communication. Between 2007 and 2019, the Oncofertility Consortium Annual Conference was held as an in-person event in Chicago, IL. The conference attracted approximately 250 attendees each year representing 20 countries around the world. In 2020, however, the COVID-19 pandemic disrupted this paradigm and precluded an in-person meeting. Nevertheless, there remained an undeniable demand for the oncofertility community to convene. To maintain the momentum of the field, the Oncofertility Consortium hosted a day-long virtual meeting on March 5, 2021, with the theme of "Oncofertility Around the Globe" to highlight the diversity of clinical care and translational research that is ongoing around the world in this discipline. This virtual meeting was hosted using the vFairs ® conference platform and allowed over 700 people to participate, many of whom were first-time conference attendees. The agenda featured concurrent sessions from presenters in six continents which provided attendees a complete overview of the field and furthered our mission to create a global community of oncofertility practice. This paper provides a synopsis of talks delivered at this event and highlights the new advances and frontiers in the fields of oncofertility and fertility preservation around the globe from clinical practice and patient-centered efforts to translational research.

A 56 year old, right handed African-American man with past history of left knee osteoarthritis, remote intravenous drug use, remote alcoholism, and seropositivity for hepatitis C was admitted to a local hospital for fatigue, chest pain, 13.6 kg weight loss, night sweats, and vision loss. On examination, a loud systolic murmur was present. An electrocardiogram (ECG) displayed T wave alternans and a transoesophageal echocardiogram revealed severe mitral regurgitation with mitral valve vegetations, ruptured chordae tendineae, and left ventricular ejection fraction of 75%. He was diagnosed as having endocarditis and cytomegalovirus endophthalmitis, and was treated with ceftriaxone, vancomycin, ganciclovir, foscarnet, aspirin, metoprolol, lisinopril, nifedipine, and intravenous esmolol. He developed fever (39.3°C) and his mental status declined. A head computed tomography (CT) scan showed left occipital haemorrhage. His left leg became cold and pale with an ankle:brachial index of 0.4. Blood cultures grew yeast. Amphotericin B was started and he was transferred to our hospital for further care. Upon arrival his temperature was 36.4°C, pulse was 80 beats per minute and regular, respiratory rate was 25 per minute, and blood pressure was 106/76 mm Hg on the right and 160/83 mm Hg on the left. On auscultation a II/VI holosystolic murmur over the apex and bibasilar rales were heard. His left leg was cold with pulses detectable only by Doppler. He was alert and oriented to person and place only, and …